Updated Jul 16, 2026 · Last SEC filing 2026-06-11
KalVista Pharmaceuticals, Inc. (KALV) has filed 30 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-11. 3 Form 8-K material event filings were reported by KALV in the last 90 days. 1 Form 144 notices of proposed sale were filed for KALV stock. InsiderAlpha tracks every KALV SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001348911 |
| Form 4 filings (90d) | 30 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-06-11 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | D — Derivative transaction | 480.0K | $0.00 | — | SEC | |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | D — Derivative transaction | 150.3K | $0.00 | — | SEC | |
| Piekos Brian | Chief Financial Officer | D — Derivative transaction | 21.7K | $0.00 | — | SEC | |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | D — Derivative transaction | 229.9K | $0.00 | — | SEC | |
| Sweeny Nicole | Chief Commercial Officer | D — Derivative transaction | 59.3K | $0.00 | — | SEC | |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | S — Open-market sale | 33.8K | $26.78 | $905K | SEC | |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | M — Option exercise | 33.8K | $7.07 | $239K | SEC | |
| Sweeny Nicole | Chief Commercial Officer | S — Open-market sale | 1.5K | $26.78 | $40K | SEC | |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | S — Open-market sale | 2.2K | $26.78 | $60K | SEC | |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | S — Open-market sale | 2.0K | $26.78 | $53K | SEC | |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | S — Open-market sale | 2.4K | $26.78 | $63K | SEC | |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | S — Open-market sale | 10.9K | $26.78 | $293K | SEC | |
| Sweeny Nicole | Chief Commercial Officer | S — Open-market sale | 1.9K | $26.78 | $50K | SEC | |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | M — Option exercise | 3.1K | — | — | SEC | |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | S — Open-market sale | 2.7K | $26.78 | $72K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for KalVista Pharmaceuticals, Inc. (KALV). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Palleiko Benjamin L | 30 | $605K |
| Yea Christopher | 23 | $1.29M |
| Audhya Paul K. | 18 | $214K |
| Sweeny Nicole | 14 | $127K |
| Unkart Edward W | 10 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in KALV insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live KALV dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.